Chartwell Investment Partners LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 32,665 shares of the company's stock after selling 1,305 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Chartwell Investment Partners LLC's holdings, making the stock its 11th largest holding. Chartwell Investment Partners LLC's holdings in Eli Lilly and Company were worth $28,939,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. Twelve Points Wealth Management LLC boosted its position in Eli Lilly and Company by 1.4% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company's stock valued at $734,000 after buying an additional 11 shares during the last quarter. Verum Partners LLC boosted its holdings in Eli Lilly and Company by 1.5% in the second quarter. Verum Partners LLC now owns 731 shares of the company's stock valued at $662,000 after acquiring an additional 11 shares during the last quarter. Beaird Harris Wealth Management LLC increased its position in Eli Lilly and Company by 2.2% in the second quarter. Beaird Harris Wealth Management LLC now owns 512 shares of the company's stock worth $464,000 after purchasing an additional 11 shares during the period. Summit Financial Strategies Inc. raised its holdings in Eli Lilly and Company by 0.5% during the 3rd quarter. Summit Financial Strategies Inc. now owns 2,105 shares of the company's stock worth $1,865,000 after purchasing an additional 11 shares during the last quarter. Finally, Prio Wealth Limited Partnership lifted its position in Eli Lilly and Company by 0.5% during the 3rd quarter. Prio Wealth Limited Partnership now owns 2,411 shares of the company's stock valued at $2,136,000 after purchasing an additional 11 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.
Shares of Eli Lilly and Company stock opened at $831.54 on Monday. The firm has a market cap of $789.40 billion, a PE ratio of 89.90, a P/E/G ratio of 3.15 and a beta of 0.43. The business's 50 day simple moving average is $896.31 and its 200 day simple moving average is $869.34. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the business earned $0.10 earnings per share. Eli Lilly and Company's revenue for the quarter was up 20.4% on a year-over-year basis. On average, analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 56.22%.
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.
Several equities research analysts have recently commented on LLY shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Redburn Atlantic raised Eli Lilly and Company to a "hold" rating in a research note on Monday, November 4th. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an "overweight" rating in a research note on Friday, August 9th. Morgan Stanley reissued an "overweight" rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, BMO Capital Markets boosted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,008.41.
View Our Latest Research Report on Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.